Vancomycin appeared to top placebo for lowering Clostridioides difficile infection (CDI) recurrence rates in patients taking ...

The FDA has approved Tyzavan, a novel ready-to-infuse, room temperature stable formulation of vancomycin, for the treatment of various bacterial infections.

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Many antimicrobial resistant pathogens are more prevalent in patients with cancer than in those without, even in the ...

Following successful trials at Geisinger Medical Center and Geisinger Wyoming Valley Medical Center, the health system will ...

The Business Research Company's Antibacterial Orthopedic Implant Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Save 30% on all global market reports with code ONLINE30 ...